The rising prevalence of
nonalcoholic fatty liver disease (
NAFLD)-related
cirrhosis highlights the need for a better understanding of the molecular mechanisms responsible for driving the transition of hepatic steatosis (
fatty liver; NAFL) to
steatohepatitis (NASH) and
fibrosis/
cirrhosis.
Obesity-related
insulin resistance (IR) is a well-known hallmark of early
NAFLD progression, yet the mechanism linking aberrant
insulin signaling to hepatocyte
inflammation has remained unclear. Recently, as a function of more distinctly defining the regulation of mechanistic pathways, hepatocyte toxicity as mediated by hepatic free
cholesterol and its metabolites has emerged as fundamental to the subsequent necroinflammation/
fibrosis characteristics of NASH. More specifically, aberrant hepatocyte
insulin signaling, as found with IR, leads to dysregulation in
bile acid biosynthetic pathways with the subsequent intracellular accumulation of mitochondrial CYP27A1-derived
cholesterol metabolites, (25R)26-hydroxycholesterol and 3β-Hydroxy-5-cholesten-(25R)26-oic
acid, which appear to be responsible for driving hepatocyte toxicity. These findings bring forth a "two-hit" interpretation as to how NAFL progresses to
NAFLD: abnormal hepatocyte
insulin signaling, as occurs with IR, develops as a "first hit" that sequentially drives the accumulation of toxic CYP27A1-driven
cholesterol metabolites as the "second hit". In the following review, we examine the mechanistic pathway by which mitochondria-derived
cholesterol metabolites drive the development of NASH. Insights into mechanistic approaches for effective NASH intervention are provided.